Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
Thor Industries
THO
$4.1B
| $10.6M | 0.01% |
+101,300
| New | +$9.81M |
|
|
CADE
1252
DELISTED
Cadence Bank
CADE
| $10.6M | 0.01% |
347,000
-299,100
| -46% | -$8.97M |
|
1253
CBIZ
CBZ
$2.96B
| $10.6M | 0.01% |
705,526
+252,869
| +56% | +$3.79M |
|
1254
Inogen
INGN
$154M
| $10.6M | 0.01% |
110,800
-101,643
| -48% | -$8.69M |
|
|
TCP
1255
DELISTED
TC Pipelines LP
TCP
| $10.6M | 0.01% |
192,199
+93,399
| +95% | +$5.34M |
|
1256
Great Southern Bancorp
GSBC
$890M
| $10.5M | 0.01% |
196,400
-2,100
| -1% | -$107K |
|
1257
EQT Corp
EQT
$34.3B
| $10.5M | 0.01% |
328,639
-654,523
| -67% | -$20.7M |
|
1258
Reinsurance Group of America
RGA
$16.3B
| $10.5M | 0.01% |
+81,500
| New | +$10.3M |
|
|
TUP
1259
DELISTED
Tupperware Brands Corporation
TUP
| $10.4M | 0.01% |
147,600
-22,200
| -13% | -$1.55M |
|
1260
Arcos Dorados Holdings
ARCO
$1.71B
| $10.3M | 0.01% |
1,427,586
+447,619
| +46% | +$3.62M |
|
1261
Booz Allen Hamilton
BAH
$9.39B
| $10.3M | 0.01% |
317,794
-40,700
| -11% | -$1.46M |
|
|
PCTI
1262
DELISTED
PCTEL, Inc. Common Stock
PCTI
| $10.3M | 0.01% |
1,460,199
+93,100
| +7% | +$653K |
|
1263
United Natural Foods
UNFI
$2.93B
| $10.3M | 0.01% |
+281,450
| New | +$11.3M |
|
|
VSA
1264
VisionSys AI
VSA
$9.58M
| $10.3M | 0.01% |
230
-95
| -29% | -$4.41M |
|
1265
Weibo
WB
$1.88B
| $10.3M | 0.01% |
+154,908
| New | +$10.1M |
|
1266
RELX
RELX
$60B
| $10.3M | 0.01% |
468,428
+90,900
| +24% | +$1.92M |
|
|
NCIT
1267
DELISTED
NCI, Inc.
NCIT
| $10.3M | 0.01% |
485,855
+81,056
| +20% | +$1.39M |
|
|
AGR
1268
DELISTED
Avangrid, Inc.
AGR
| $10.2M | 0.01% |
232,000
+150,900
| +186% | +$6.7M |
|
|
FUEL
1269
DELISTED
Rocket Fuel Inc.
FUEL
| $10.2M | 0.01% |
3,712,700
+359,400
| +11% | +$1.34M |
|
|
TRST
1270
Trustco Bank Corp NY
TRST
$979M
| $10.2M | 0.01% |
263,080
+4,480
| +2% | +$174K |
|
|
ALE
1271
DELISTED
Allete
ALE
| $10.2M | 0.01% |
141,900
+1,800
| +1% | +$128K |
|
1272
Oracle
ORCL
$441B
| $10.2M | 0.01% |
+202,632
| New | +$9.23M |
|
1273
Arrow Financial
AROW
$728M
| $10.1M | 0.01% |
393,518
+21,400
| +6% | +$575K |
|
1274
Financial Institutions
FISI
$831M
| $10.1M | 0.01% |
339,800
+106,200
| +45% | +$3.36M |
|
|
ATSG
1275
DELISTED
Air Transport Services Group
ATSG
| $10.1M | 0.01% |
462,300
+261,900
| +131% | +$5.47M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.